Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) is scheduled to announce its earnings results before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02. During the same period in the prior year, the firm earned ($0.11) earnings per share. On average, analysts expect Nautilus Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Nautilus Biotechnology Trading Down 1.6 %
NAUT stock opened at $2.42 on Tuesday. The stock has a market capitalization of $302.74 million, a PE ratio of -4.65 and a beta of 1.20. Nautilus Biotechnology has a 12-month low of $2.16 and a 12-month high of $4.65. The stock’s 50 day simple moving average is $2.69 and its 200 day simple moving average is $2.82.
Insider Activity at Nautilus Biotechnology
About Nautilus Biotechnology
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
See Also
- Five stocks we like better than Nautilus Biotechnology
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Merger or Not, Albertson’s Companies is a Good Buy
- 3 Small Caps With Big Return Potential
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.